Schrödinger (SDGR) Competitors

Schrödinger (NASDAQ:SDGR) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings, community ranking and media sentiment.

Do analysts rate SDGR or SAGE?

Schrödinger currently has a consensus price target of $33.44, indicating a potential upside of 60.48%. Sage Therapeutics has a consensus price target of $16.06, indicating a potential upside of 103.28%. Given Sage Therapeutics' higher possible upside, analysts plainly believe Sage Therapeutics is more favorable than Schrödinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrödinger	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.80
Sage Therapeutics	2 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.95

Which has more volatility & risk, SDGR or SAGE?

Schrödinger has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Is SDGR or SAGE more profitable?

Schrödinger has a net margin of -100.42% compared to Sage Therapeutics' net margin of -458.30%. Schrödinger's return on equity of -38.38% beat Sage Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrödinger	-100.42%	-38.38%	-26.66%
Sage Therapeutics	-458.30%	-55.87%	-50.00%

Does the MarketBeat Community believe in SDGR or SAGE?

Sage Therapeutics received 578 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 66.56% of users gave Sage Therapeutics an outperform vote while only 56.04% of users gave Schrödinger an outperform vote.

Company	Underperform	Outperform
Schrödinger	Outperform Votes 51 56.04%	Underperform Votes 40 43.96%
Sage Therapeutics	Outperform Votes 629 66.56%	Underperform Votes 316 33.44%

Which has higher earnings & valuation, SDGR or SAGE?

Schrödinger has higher revenue and earnings than Sage Therapeutics. Schrödinger is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrödinger	$216.67M	7.00	$40.72M	-$1.88	-11.09
Sage Therapeutics	$86.46M	5.58	-$541.49M	-$8.40	-0.94

Does the media favor SDGR or SAGE?

In the previous week, Sage Therapeutics had 19 more articles in the media than Schrödinger. MarketBeat recorded 22 mentions for Sage Therapeutics and 3 mentions for Schrödinger. Schrödinger's average media sentiment score of 0.21 beat Sage Therapeutics' score of 0.08 indicating that Schrödinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrödinger	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sage Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders believe in SDGR or SAGE?

79.1% of Schrödinger shares are held by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are held by institutional investors. 8.6% of Schrödinger shares are held by insiders. Comparatively, 5.5% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Schrödinger beats Sage Therapeutics on 13 of the 19 factors compared between the two stocks.